PNC Financial Services Group
INZY

PNC Financial Services Group’s Inozyme Pharma INZY Stock Holding History

PNC Financial Services Group’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3,725
Closed -$14.9K – 5153
2025
Q2 		$14.9K Buy
3,725
+3,136
+532% +$7.77K ﹤0.01% 3702
2025
Q1 		$536 Buy
589
+554
+1,583% +$768 ﹤0.01% 4631
2024
Q4 		$97 Hold
35
– – ﹤0.01% 4710
2024
Q3 		$183 Hold
35
– – ﹤0.01% 4687
2024
Q2 		$156 Buy
+35
New +$170 ﹤0.01% 4694
2021
Q2 		– Sell
-9,136
Closed -$180K – 4229
2021
Q1 		$180K Hold
9,136
– – ﹤0.01% 2227
2020
Q4 		$188K Buy
+9,136
New +$218K ﹤0.01% 2105

PNC Financial Services Group's INZY Position: Q3 2025 in Review

PNC Financial Services Group sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 3,725 shares — an estimated $14.9K sold.

PNC Financial Services Group first reported a position in INZY in Q4 2020 and held it in 7 quarters. The position peaked at $188K in Q4 2020. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

  • PNC Financial Services Group reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
  • PNC Financial Services Group sold 3,725 Inozyme Pharma shares in Q3 2025, an estimated $14.9K.
  • PNC Financial Services Group first reported a position in Inozyme Pharma in Q4 2020 and held it in 7 quarters.
  • PNC Financial Services Group's Inozyme Pharma position peaked at $188K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on PNC Financial Services Group's 13F filing for Q3 2025, filed 7 Nov 2025.